BBIO

68.56

3.59% -2.55

Handel nachbörslich: 68.35 -0.21 -0.31%

Bridgebio Pharma Inc (BBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BBIO? Forum Prognose

Schlusskurs vom Vortag:

$71.11

Offen:

$70.51

24-Stunden-Volumen:

1.80M

Relative Volume:

0.68

Marktkapitalisierung:

$13.29B

Einnahmen:

$502.08M

Nettoeinkommen (Verlust:

$-732.94M

KGV:

-18.12

EPS:

-3.7842

Netto-Cashflow:

$-455.50M

1W Leistung:

-6.44%

1M Leistung:

-7.91%

6M Leistung:

+9.45%

1J Leistung:

+78.54%

1-Tages-Spanne:

$68.41

$70.95

1-Wochen-Bereich:

$68.35

$84.75

52-Wochen-Spanne:

$31.77

$84.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Firmenname

Bridgebio Pharma Inc

Sektor

Healthcare (1113)

Branche

Biotechnology (622)

Telefon

(650) 391-9740

Adresse

3160 PORTER DR., PALO ALTO, CA

Mitarbeiter

839

Twitter

Nächster Verdiensttermin

2026-05-07

Neueste SEC-Einreichungen

BBIO's Discussions on Twitter

Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BBIO Bridgebio Pharma Inc	68.56	13.29B	502.08M	-732.94M	-455.50M	-3.7842
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-09	Eingeleitet	RBC Capital Mkts	Outperform
2026-03-10	Eingeleitet	William Blair	Outperform
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-06	Eingeleitet	Morgan Stanley	Overweight
2025-12-11	Eingeleitet	Bernstein	Outperform
2025-07-30	Fortgesetzt	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-07-14	Eingeleitet	Jefferies	Buy
2025-07-09	Hochstufung	Oppenheimer	Perform → Outperform
2025-06-17	Eingeleitet	Wolfe Research	Outperform
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-10-03	Eingeleitet	Oppenheimer	Perform
2024-09-04	Eingeleitet	Piper Sandler	Overweight
2024-03-21	Fortgesetzt	Raymond James	Outperform
2024-01-31	Eingeleitet	BMO Capital Markets	Market Perform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-11-07	Eingeleitet	Citigroup	Buy
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-07-18	Herabstufung	Jefferies	Buy → Hold
2023-04-19	Eingeleitet	Evercore ISI	Outperform
2023-02-06	Eingeleitet	Cowen	Outperform
2021-12-27	Bestätigt	Mizuho	Buy
2021-12-27	Bestätigt	SVB Leerink	Outperform
2021-09-10	Hochstufung	BofA Securities	Neutral → Buy
2021-05-21	Eingeleitet	UBS	Buy
2021-03-22	Bestätigt	Goldman	Buy
2021-02-22	Fortgesetzt	JP Morgan	Overweight
2021-02-09	Fortgesetzt	Goldman	Buy
2021-01-11	Bestätigt	H.C. Wainwright	Buy
2020-12-10	Bestätigt	H.C. Wainwright	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Neutral
2020-05-19	Eingeleitet	BTIG Research	Buy
2020-04-13	Eingeleitet	H.C. Wainwright	Buy
2020-02-19	Eingeleitet	Mizuho	Buy
2019-07-26	Eingeleitet	Raymond James	Outperform
2019-07-22	Eingeleitet	BMO Capital Markets	Outperform
2019-07-22	Eingeleitet	Goldman	Buy
2019-07-22	Eingeleitet	JP Morgan	Overweight
2019-07-22	Eingeleitet	Jefferies	Buy
2019-07-22	Eingeleitet	Piper Jaffray	Overweight
2019-07-22	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

01:14 AM

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN

01:14 AM

May 01, 2026

BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN

May 01, 2026

Vanguard Group Inc. Increases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat

May 01, 2026

Apr 30, 2026

BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 30, 2026

Truist Financial Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $102 - Moomoo

Apr 30, 2026

Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail

Apr 30, 2026

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET - The Manila Times

Apr 30, 2026

After the bell: BridgeBio schedules Q1 results and program update - Stock Titan

Apr 30, 2026

Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)? - Yahoo Finance

Apr 30, 2026

The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media

Apr 30, 2026

Apr 29, 2026

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha

Apr 29, 2026

BridgeBio rises after late-stage trial win for dwarfism therapy - MSN

Apr 29, 2026

BridgeBio Pharma Is Maintained at Buy by Truist Securities - Moomoo

Apr 29, 2026

BridgeBio earnings on deck: Can Attruby sustain rapid growth? By Investing.com - Investing.com South Africa

Apr 29, 2026

BridgeBio earnings on deck: Can Attruby sustain rapid growth? - Investing.com

Apr 29, 2026

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail

Apr 29, 2026

BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus

Apr 29, 2026

Truist Financial Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat

Apr 29, 2026

BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus

Apr 29, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 29, 2026

H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook - Investing.com Canada

Apr 29, 2026